Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Travere Therapeutics reported revenue of $491M in the fiscal year ended Dec 2025, up 110.5% from the year before. Operating income was −$63M, an operating margin of −12.8%, and net income was −$26M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 132 | 109 | 145 | 233 | 491 |
| Cost of revenue | 3.8 | 4.4 | 11.5 | 7.7 | 10.3 |
| Gross profit | 128 | 105 | 134 | 225 | 480 |
| Research & development | 201 | 7.5 | 245 | 217 | 206 |
| Selling, general & admin | 126 | 198 | 266 | 264 | 337 |
| Operating income | −199 | −320 | −388 | −324 | −62.8 |
| Interest expense | 19.7 | 11.0 | 11.3 | 11.2 | 10.7 |
| Pre-tax income | −217 | −331 | −376 | −321 | −49.3 |
| Income tax | 0.4 | 0.3 | 0.2 | 0.1 | 1.0 |
| Net income | −180 | −278 | −111 | −322 | −25.5 |
| Diluted EPS | −3.01 | −4.37 | −1.50 | −4.08 | −0.29 |
| Diluted shares | 59.8 | 63.8 | 74.3 | 78.9 | 89.2 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 166 | 61.7 | 58.2 | 58.5 | 93.0 |
| Receivables | 15.9 | 16.6 | 21.2 | 27.1 | 80.1 |
| Inventory | 7.3 | 4.5 | 9.4 | 41.9 | 36.2 |
| Current assets | 583 | 486 | 617 | 417 | 438 |
| Net PP&E | 11.1 | 9.0 | 7.5 | 5.3 | 4.0 |
| Goodwill | 0.9 | 0.8 | 0.8 | 0.8 | – |
| Total assets | 777 | 673 | 789 | 594 | 605 |
| Payables | 15.1 | 17.3 | 41.7 | 23.5 | 24.8 |
| Deferred revenue | 16.3 | 12.0 | 7.1 | 2.8 | 0.0 |
| Current liabilities | 124 | 142 | 178 | 201 | 160 |
| Total liabilities | 475 | 630 | 588 | 535 | 490 |
| Shareholders' equity | 302 | 42.9 | 201 | 59.1 | 115 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −14.8 | −186 | −280 | −237 | 37.8 |
| Capital expenditure | 5.1 | 0.2 | 0.7 | – | – |
| Free cash flow | −19.9 | −186 | −281 | – | – |
| Depreciation & amortisation | 12.7 | 20.7 | 38.5 | 43.6 | 60.7 |
| Stock-based compensation | 29.6 | 38.1 | 44.2 | 36.9 | 44.9 |
| Acquisitions | 0.0 | 0.0 | – | – | – |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | −17.0% | 32.7% | 60.5% | 110.5% |
| Gross margin | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating margin | −151.3% | −292.2% | −267.2% | −138.9% | −12.8% |
| Net margin | −136.6% | −254.4% | −76.7% | −137.9% | −5.2% |
| Return on equityBlank when equity is negative | −59.6% | −649.9% | −55.5% | −544.3% | −22.2% |
| ROCEEBIT ÷ (assets − current liabilities) | −30.6% | −60.3% | −63.5% | −82.3% | −14.1% |
| Free cash flow margin | −15.1% | −170.4% | −193.3% | – | – |
| Cash conversion (CFO ÷ net income) | 0.08x | 0.67x | 2.51x | 0.74x | −1.48x |
| Receivable days | 44 | 56 | 53 | 42 | 60 |
| Inventory days | 699 | 374 | 300 | 1973 | 1276 |
| Payable days | 1448 | 1428 | 1329 | 1109 | 876 |
| Interest cover | −10.1x | −29.1x | −34.3x | −29.0x | −5.85x |
| Current ratio | 4.70x | 3.42x | 3.47x | 2.08x | 2.74x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.